转运体在药物排泄中的作用及在新药研发中的意义

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (4): 448-454.

转运体在药物排泄中的作用及在新药研发中的意义

王磊, 李宁, 陈西敬

中国药科大学药物代谢与动力学研究中心, 南京210009, 江苏

收稿日期:2009-03-03 修回日期:2009-04-29 发布日期:2020-10-29
通讯作者: 陈西敬,男,教授,博士生导师,研究方向:药物代谢动力学。Tel:025-83271286 E-mail:chen-lab@hotmail.com
作者简介:王磊,男,硕士研究生,研究方向:药物代谢动力学。 E-mail:wallyphinex@sina.com
基金资助:
国家高技术研究发展计划(“863”计划)(2007AA02Z171);国家自然科学基金(30472060)的资助

Role of transporters in the drug excretion and its significance in new drug development

WANG Lei , LI Ning , CHEN Xi-jing

Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, Jiangsu,China

Received:2009-03-03 Revised:2009-04-29 Published:2020-10-29

摘要/Abstract

摘要： 本文介绍了药物转运体在药物排泄过程中的作用,探讨了其在新药研发和临床应用中的可能性。通过对药物转运体功能的了解和利用,可以开发出对某些器官有靶向性的药物,或避免药物分布到某些器官中,从而提高药物的疗效,降低其毒副作用;也可以通过对转运体介导的药物相互作用及肝肠循环的研究,指导临床更加安全有效的用药。在药物研发的初始阶段,就开始重视其药动学特性,这一观念近年来已被很多人所接受。对药物转运体的深入认识和利用,建立高通量的药物转运体筛选体系,对于加速新药研发的进程将具有极其重要的意义。

关键词: 药物转运体, 肝胆排泄, 肾排泄, 药物靶向性

Abstract: This review is mainly concerned about the effects of drug transporters on drug excretion and the possibility in the development and clinical application of new drugs.The understanding of the properties of transporters enables us to develop novel drugs , which can increase the site-directional drug delivery , or avoid the distribution to other organs , thereby increase the therapeutic effects and reduce the chance of toxic effects.Furthermore , the research of drug transporter- mediated drug-drug interactions and enterohepatic cycle , is able to guide us a more reasonable , safe and effective clinical medication.It is well accepted in recent years that the pharmacokinetic properties of a new drug should be studied in its early stage of development.Additionally , high-through screening system established on transporters is bound to be an effective tool to accelerate the development of new drugs.

Key words: drug transporter, hepatic biliary excretion, renal excretion, drug targeting

中图分类号:

R969.1

王磊, 李宁, 陈西敬. 转运体在药物排泄中的作用及在新药研发中的意义[J]. 中国临床药理学与治疗学, 2009, 14(4): 448-454.

WANG Lei , LI Ning , CHEN Xi-jing. Role of transporters in the drug excretion and its significance in new drug development[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(4): 448-454.

参考文献

[1] Sekine T, Miyazaki H, Endou H.Molecular physiology of renal organic anion transporters[J].Am J Physiol Renal Physiol, 2006, 290(2):F251-F261.
[2] Choudhuri S, Klaassen CD.Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP)efflux transporters[J].Int J Toxicol,2006, 25(4):231-259.
[3] Sweet DH.Organic anion transporter (Slc22a)family members as mediators of toxicity[J].Toxicol Appl Pharmacol, 2005, 204(3):198-215.
[4] Shitara Y, Horiea T, Sugiyama Y.Transporters as a determinant of drug clearance and tissue distribution[J].Eur J Pharm Sci, 2006, 27(5):425-446.
[5] Funk C, Ponelle C, Scheuermann G, et a1.Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity:in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep)in the rat[J].Mol Pharmacol, 2001, 59(3):627-635.
[6] Wang DS, Kusuhara H, Kato Y, et al.Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin[J].Mol Pharmacol, 2003, 63(4):844-848.
[7] Vavricka SR, Van Montfoort J, Ha HR, et a1.Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver[J].Hepatology, 2002, 36 (1):164-172.
[8] Kajinami K, Takekoshi N, Saito Y.Pitavastatin:efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor[J].Cardiovasc Drug Rev, 2003, 21(3):199-215.
[9] Dominguez MF, Macias RI, Izco-Basurko I, et al.Low in vivo toxicity of a novel cisplatin-ursodeoxy cholic derivative (Bamet-UD2).with enhanced cytostatic activity versus liver tumors[J].J Pharmacol Exp Ther, 2001, 297 (3):1106-1112.
[10] Nakanishi T, Tamai I, Takaki A, et al.Cancer cell-targeted drug delivery utilizing oligopeptide transport activity [J].Int J Cancer, 2000, 88(2):274-280.
[11] Yamada I, Fukunari A, Osajima T, et al.Pharmacokinetics pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man[J].Nucleosides Nucleotides Nucleic Acids, 2004, 23(8 9):1123-1125.
[12] Sai Y, Kato Y, Nakamura K, et al.Carrier-mediated hepatic uptake of a novel nonrenal excretion type uric acid generation inhibitor, Y-700[J].J Pharm Sci, 2006, 95 (2):336-347.
[13] Marchetti S, Mazzanti R, Beijnen JH, et al.Concise review:Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-gly coprotein)[J].Oncologist, 2007, 12(8):927-941.
[14] Shitara Y, Hirano M, Sato H, et a1.Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2 OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analy sis of the mechanism of the clinically relevant drugdrug interaction between cerivastatin and gemfibrozil[J].J Pharmacol Exp Ther, 2004, 311(1):228-236.
[15] Farkas D, Greenblatt DJ.Influence of fruit juices on drug disposition:discrepancies between in vitro and clinical studies[J].Expert Opin Drug Metab Toxicol, 2008, 4 (4):381-393.
[16] 范岚, 谢海棠, 周宏灏.中西药合用治疗肿瘤的相互作用及其机制探讨[J].中国临床药理学与治疗学,2007, 12(2):134-139.
[17] 毛晓琴, 谢海棠, 周宏灏.多药耐药蛋白和CYP3A4介导的中草药-西药相互作用[J].中国临床药理学与治疗学, 2007, 12(7):728-734.
[18] Yang XX, Hu ZP, Duan W, et a1.Drug-herb interactions: eliminating toxicity with hard drug design[J].Curr Pharm Des, 2006, 12(35):4649-4664.
[19] Huang SM, Strong JM, Zhang L, et al.New era in drug interaction evaluation:US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process[J].J Clin Pharmacol, 2008, 48(6):662-670.
[20] Huang SM, Temple R, Throckmorton DC, et al.Drug interaction studies:study design, data analysis, and implications for dosing and labeling[J].Clin Pharmacol Ther, 2007, 81(2):298-304.
[21] Hammerle SP, Rothen RB, Kramer SD, et al.P-Gly coprotein in cell cultures:a combined approach to study expression, localisation, and functionality in the confocal microscope[J].Eur J Pharm Sci, 2000, 12(1):69-77.
[22] 周昕.药物吸收体外研究方法的概述[J].中国临床药理学与治疗学, 2006, 11(4):379-384.
[23] Chang C, Swaan PW.Computational approaches to modeling drug transporters[J].Eur J Pharm Sci, 2006, 27(5): 411-424.
[24] 马秉亮, 吴玉林, 刘国卿.P-gp 及对抗P-gp 介导多药耐药的研究现状[J].中国临床药理学与治疗学,2006, 11(1):14-21.
[25] DemelMA, Schwaha R, Kr?mer O, et a1.In silico prediction of substrate properties for ABC-multidrug transporters[J].Expert Opin Drug Metab Toxicol, 2008, 4(9):1167-1180.